Patents by Inventor Jay Xu
Jay Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11984955Abstract: A method of wireless communication, by a user equipment (UE), includes receiving multiple neural network training configurations for channel state feedback (CSF). Each configuration corresponds to a different neural network framework. The method also includes training each of a group of neural network decoder/encoder pairs in accordance with the received training configurations. A method of wireless communication, by a base station, includes transmitting multiple neural network training configurations to a user equipment (UE) for channel state feedback (CSF). Each configuration corresponds to a different neural network framework. The method also includes receiving a neural network decoder/encoder pair trained in accordance with the training configurations.Type: GrantFiled: April 17, 2020Date of Patent: May 14, 2024Assignee: QUALCOMM IncorporatedInventors: Bo Chen, Pavan Kumar Vitthaladevuni, Taesang Yoo, Naga Bhushan, Jay Kumar Sundararajan, Ruifeng Ma, June Namgoong, Krishna Kiran Mukkavilli, Hao Xu, Tingfang Ji
-
Patent number: 11974256Abstract: Certain aspects of the present disclosure provide techniques for scheduling and bandwidth part (BWP) adaptation for extended reality (XR). A method that may be performed by a user equipment (UE) includes obtaining an indication to change at least one of a minimum control-channel-to-data-channel delay or a bandwidth for receiving a first transmission on a BWP; changing the at least one of the minimum control-channel-to-data-channel delay to a new minimum control-channel-to-data-channel delay or the bandwidth on the BWP to a new bandwidth; and receiving the first transmission on the BWP using the at least one of the new minimum control-channel-to-data-channel delay or the new bandwidth of the BWP.Type: GrantFiled: April 12, 2021Date of Patent: April 30, 2024Assignee: QUALCOMM IncorporatedInventors: Hwan Joon Kwon, Huilin Xu, Yuchul Kim, Peter Pui Lok Ang, Yeliz Tokgoz, Jay Kumar Sundararajan, Krishna Kiran Mukkavilli, Tingfang Ji, Jing Lei, Ravi Agarwal, Seyong Park, Seyedkianoush Hosseini
-
Patent number: 11956649Abstract: Certain aspects of the present disclosure provide techniques for remote interference mitigation between base stations using reference signals. Certain aspects provide a method for wireless communication by a first base station (BS). The method includes receiving a reference signal (RS) from a second BS. The method further includes performing interference measurement corresponding to interference from the second BS based on the RS being associated with the second BS.Type: GrantFiled: July 28, 2018Date of Patent: April 9, 2024Assignee: QUALCOMM IncorporatedInventors: Hung Dinh Ly, Huilin Xu, Joseph Binamira Soriaga, Tingfang Ji, Peter Gaal, Jay Kumar Sundararajan, Yeliz Tokgoz, Naga Bhushan, Yuwei Ren
-
Publication number: 20240089766Abstract: Methods, systems, and devices for wireless communications are described. A communication device, otherwise known as a user equipment (UE) may transmit capability information including an indication of a discontinuous monitoring delay period. The UE may receive a message including an indication to adjust monitoring of a physical downlink control channel (PDCCH), and monitor for the PDCCH during the discontinuous monitoring delay period. The UE may adjust monitoring for the PDCCH following the discontinuous monitoring delay period during a temporal period based on the received indication to adjust monitoring of the PDCCH. In some examples, at least one of physical downlink shared channel (PDSCH) reception, downlink reference signal monitoring, uplink reference signal transmissions, and channel reporting is enabled during the temporal period while monitoring of the PDCCH is adjusted.Type: ApplicationFiled: November 17, 2023Publication date: March 14, 2024Inventors: Yuchul KIM, Huilin XU, Hwan Joon KWON, Peter Pui Lok ANG, Jay Kumar SUNDARARAJAN, Krishna Kiran MUKKAVILLI, Yeliz TOKGOZ, Jing LEI, Tingfang JI, Ravi AGARWAL, Seyong PARK
-
Patent number: 11917638Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may determine a downlink configuration including a set of resources for receiving downlink transmissions. The UE may determine, based on the downlink configuration, an uplink configuration including a set of resources for transmitting scheduling requests at a set of scheduling request occasions. In some aspects, the set of scheduling request occasions may be arranged according to a non-uniform spacing pattern in the time domain. The UE may transmit, to a base station, one or more scheduling requests based on the uplink configuration.Type: GrantFiled: September 14, 2021Date of Patent: February 27, 2024Assignee: QUALCOMM IncorporatedInventors: Yuchul Kim, Peter Pui Lok Ang, Hwan Joon Kwon, Krishna Kiran Mukkavilli, Jay Kumar Sundararajan, Yeliz Tokgoz, Linhai He, Huilin Xu, Jing Lei
-
Patent number: 11917637Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may determine a downlink configuration including a set of resources for receiving downlink transmissions. The UE may determine a grant for performing uplink transmissions based on a radio resource control (RRC) message. The UE may determine, based on the downlink configuration, the grant, or both, an uplink configuration including a set of resources for transmitting the uplink transmissions at a set of uplink transmission occasions. In some aspects, the set of uplink transmission occasions may be arranged according to a non-uniform spacing pattern in a time domain. The UE may transmit, to a base station, one or more uplink transmissions based on the uplink configuration.Type: GrantFiled: September 14, 2021Date of Patent: February 27, 2024Assignee: QUALCOMM IncorporatedInventors: Yuchul Kim, Peter Pui Lok Ang, Linhai He, Hwan Joon Kwon, Krishna Kiran Mukkavilli, Yeliz Tokgoz, Jay Kumar Sundararajan, Huilin Xu, Jing Lei
-
Publication number: 20200247755Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: ApplicationFiled: September 11, 2019Publication date: August 6, 2020Inventors: Bradley Teegarden, Dennis Chapman, Marc Decaire, Peter I. Dosa, Konrad Feichtinger, Honnappa Jayakumar, Thuy-Anh Tran, Sonja Strah-Pleynet, Jay Xu
-
Patent number: 10450276Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: GrantFiled: August 22, 2016Date of Patent: October 22, 2019Assignee: Arena Pharmaceuticals, Inc.Inventors: Bradley Teegarden, Dennis Chapman, Marc Decaire, Peter I. Dosa, Konrad Feichtinger, Honnappa Jayakumar, Thuy-Anh Tran, Sonja Strah-Pleynet, Jay Xu
-
Publication number: 20190070149Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: ApplicationFiled: April 26, 2018Publication date: March 7, 2019Inventors: Bradley Teegarden, Dennis Chapman, Juyi Choi, Konrad Feichtinger, Sangdon Han, Honnappa Jayakumar, Thuy-Anh Tran, Jay Xu, Ning Zou
-
Patent number: 9987252Abstract: The present invention pertains to certain compounds of Formula (Ia), and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infraction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: GrantFiled: August 15, 2016Date of Patent: June 5, 2018Assignee: Arena Pharmaceuticals, Inc.Inventors: Bradley Teegarden, Dennis Chapman, Juyi Choi, Konrad Feichtinger, Sangdon Han, Honnappa Jayakumar, Thuy-Anh Tran, Jay Xu, Ning Zou
-
Publication number: 20170189381Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: ApplicationFiled: August 15, 2016Publication date: July 6, 2017Inventors: Bradley Teegarden, Dennis Chapman, Juyi Choi, Konrad Feichtinger, Sangdon Han, Honnappa Jayakumar, Thuy-Anh Tran, Jay Xu, Ning Zou
-
Patent number: 9328107Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: GrantFiled: January 28, 2014Date of Patent: May 3, 2016Assignee: Arena Pharmaceuticals, Inc.Inventors: Bradley Teegarden, Dennis Chapman, Juyi Choi, Konrad Feichtinger, Sangdon Han, Honnappa Jayakumar, Thuy-Anh Tran, Jay Xu, Ning Zou
-
Patent number: 9221755Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: GrantFiled: February 18, 2014Date of Patent: December 29, 2015Assignee: Arena Pharmaceuticals, Inc.Inventors: Bradley Teegarden, Dennis Chapman, Marc Decaire, Peter I. Dosa, Konrad Feichtinger, Honnappa Jayakumar, Thuy-Anh Tran, Sonja Strah-Pleynet, Jay Xu
-
Publication number: 20150265576Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: ApplicationFiled: February 27, 2015Publication date: September 24, 2015Inventors: Bradley Teegarden, Dennis Chapman, Juyi Choi, Konrad Feichtinger, Sangdon Han, Honnappa Jayakumar, Thuy-Anh Tran, Jay Xu, Ning Zou
-
Publication number: 20150174102Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: ApplicationFiled: February 27, 2015Publication date: June 25, 2015Inventors: Bradley Teegarden, Dennis Chapman, Marc Decaire, Peter I. Dosa, Konrad Feichtinger, Honnappa Jayakumar, Thuy-Anh Tran, Sonja Strah-Pleynet, Jay Xu
-
Publication number: 20140235622Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: ApplicationFiled: January 28, 2014Publication date: August 21, 2014Applicant: Arena Pharmaceuticals, Inc.Inventors: Bradley Teegarden, Dennis Chapman, Juyi Choi, Konrad Feichtinger, Sangdon Han, Honnappa Jayakumar, Thuy-Anh Tran, Jay Xu, Ning Zou
-
Publication number: 20140163032Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: ApplicationFiled: February 18, 2014Publication date: June 12, 2014Applicant: ARENA PHARMACEUTICALS, INC.Inventors: BRADLEY TEEGARDEN, Dennis Chapman, Marc Decaire, Peter I. Dosa, Konrad Feichtinger, HONNAPPA JAYAKUMAR, THUY-ANH Tran, Sonja Strah-Pleynet, Jay Xu
-
Patent number: 8664258Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: GrantFiled: March 9, 2012Date of Patent: March 4, 2014Assignee: Arena Pharmaceuticals, Inc.Inventors: Bradley Teegarden, Dennis Chapman, Juyi Choi, Konrad Feichtinger, Sangdon Han, Honnappa Jayakumar, Thuy-Anh Tran, Jay Xu, Ning Zou
-
Patent number: RE45336Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: GrantFiled: November 27, 2013Date of Patent: January 13, 2015Assignee: Arena Pharmaceuticals, Inc.Inventors: Bradley Teegarden, Dennis Chapman, Juyi Choi, Konrad Feichtinger, Sangdon Han, Honnappa Jayakumar, Thuy-Anh Tran, Jay Xu, Ning Zou
-
Patent number: RE45337Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.Type: GrantFiled: November 27, 2013Date of Patent: January 13, 2015Assignee: Arena Pharmaceuticals, Inc.Inventors: Bradley Teegarden, Dennis Chapman, Marc Decaire, Peter I. Dosa, Konrad Feichtinger, Honnappa Jayakumar, Thuy-Anh Tran, Sonja Strah-Pleynet, Jay Xu